Lexeo (LXEO) CFO Louis E. Tamayo Sells 4,117 Shares

What Happened

• Louis E. Tamayo, Chief Financial Officer of Lexeo Therapeutics (LXEO), sold 4,117 shares on August 18, 2026. The weighted-average sale price was $4.91 per share for total proceeds of approximately $20,203. This transaction is reported as a sale to cover tax obligations related to the release of restricted stock units (RSUs).

Key Details

• Transaction date: 2026-08-18 (filed 2026-08-19; timely filing)
• Shares sold: 4,117; weighted-average price: $4.91; price range across trades: $4.83–$5.01
• Total proceeds: ~$20,203
• Reason/footnote: Sale to cover tax withholding on RSU release (F1). Transaction executed in multiple trades; reporting person can provide per-trade breakdown on request (F2).
• Holdings note: Filing indicates the reporting person's holdings include 78,415 restricted stock units (F3). The filing does not list a full post-transaction total share count.

Context

• This was a routine, tax-withholding sale tied to RSU vesting rather than a discretionary open‑market sell for investment reasons. Such transactions are common when companies or insiders use share sales to satisfy tax obligations and are not by themselves a clear signal about the insider’s view of the company.